Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 2
2007 1
2009 3
2010 2
2012 4
2013 4
2014 5
2015 2
2016 1
2017 3
2018 2
2019 3
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Ten simple rules to power drug discovery with data science.
Ferrero E, Brachat S, Jenkins JL, Marc P, Skewes-Cox P, Altshuler RC, Gubser Keller C, Kauffmann A, Sassaman EK, Laramie JM, Schoeberl B, Borowsky ML, Stiefl N. Ferrero E, et al. Among authors: schoeberl b. PLoS Comput Biol. 2020 Aug 27;16(8):e1008126. doi: 10.1371/journal.pcbi.1008126. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32853229 Free PMC article. No abstract available.
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, Welin M, Chattopadhyay S, Harms BD, Nielsen UB, Schoeberl B, Lugovskoy AA, MacBeath G. Casaletto JB, et al. Among authors: schoeberl b. Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7533-7542. doi: 10.1073/pnas.1819085116. Epub 2019 Mar 21. Proc Natl Acad Sci U S A. 2019. PMID: 30898885 Free PMC article.
Predicting ligand-dependent tumors from multi-dimensional signaling features.
Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A. Hass H, et al. Among authors: schoeberl b. NPJ Syst Biol Appl. 2017 Sep 20;3:27. doi: 10.1038/s41540-017-0030-3. eCollection 2017. NPJ Syst Biol Appl. 2017. PMID: 28944080 Free PMC article.
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G. Schoeberl B, et al. NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. NPJ Syst Biol Appl. 2017. PMID: 28725482 Free PMC article. Review.
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA. Camblin AJ, et al. Among authors: schoeberl b. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549161 Free article.
34 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page